-
Aiming for a Cure: How CD74 Research Could Eliminate Drug-Resistant Lung Cancer for Good
Read time: 4 minutes.
Lung cancer remains the leading cause of cancer death worldwide. Over the past two decades, the development of targeted therapies, particularly tyrosine kinase inhibitors (TKIs...
IN THE SPOTLIGHT
-
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
Read time: 3 minutes. For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are... -
6 Tips for Managing Scanxiety
Read time: 4 minutes. Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as... -
Sharing Experiences With EGFR Lung Cancer: A Tool Shaped by Patients and Caregivers
Why did we build a tool to visualize data collected from patients and caregivers? Community members provide data but too often never see how their data was used. Research data is... -
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming... -
EGFR Virtual Meetup
EGFR patients/survivors - Join us the 1st Wednesday of every month to connect with others who share common experiences and build your community. -
New Treatment for Patients with Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
On July 2, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of sunvozertinib (Zegfrovy®) to treat patients with locally advanced or metastatic non... -
Understanding DTPCs: A Path to Ending Drug Resistance in Lung Cancer
When a person is treated for advanced-stage lung cancer, tumors will often shrink, and their symptoms may subside. An effective treatment will kill many tumor cells, but there are... -
New ADC Treatment Approved for Advanced EGFR+ NSCLC
On June 23, 2025, the US Food and Drug Administration (FDA) announced the approval of datopotamab deruxtecan-dlnk (Datroway® or Dato-DXd) to treat patients with locally advanced or...